Robins Kaplan Miller & Ciresi adds IP litigator

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Robins Kaplan Miller & Ciresi adds IP litigator

paul20gibbons.jpg

Robins Kaplan Miller & Ciresi has added IP litigator Paul Gibbons to the firm’s Boston office.

Gibbons, previously a shareholder with Niro Haller & Niro, focuses mainly on patent litigation, but also practices copyright, trade mark, trade secret and trade dress litigation. He also does negotiation, mediation, and licensing.

Earlier in his career, Gibbons worked for GE Aerospace, GE Aircraft Engines and GE Industrial and Power Systems.

more from across site and SHARED ros bottom lb

More from across our site

The firm said adding capability in the French capital completes its coverage of all major patent litigation jurisdictions as it strives for UPC excellence
Marc Fenster explains how keeping the jury focused on the most relevant facts helped secure a $279m win for his client against Samsung
Clients are divided on what externally funded IP firms bring to the table, so those firms must prove why the benefits outweigh the downsides
Rahul Bhartiya, AI coordinator at the EUIPO, discusses the office’s strategy, collaboration with other IP offices, and getting rid of routine tasks
A boom in transactional work and a heightened awareness of IP have helped boost revenue for the rebranded commercial services team
Clemens Heusch, head of global litigation and dispute resolution at Nokia, tells us why open conversations – and respectful challenges – lead to the best results
Siegmund Gutman, who joined Mintz one year ago, explains the firm’s approach to life sciences litigation and what it means for hiring plans
The merger of two IP boutiques could prompt others to follow suit and challenge Australia’s externally funded firms
Law firm leaders say they are eager to make the most out of the market following a 'surprising' survey on in-house interest in IP monetisation
A defeat for AstraZeneca and Open Innovation Network's 20th anniversary were also among the top talking points this week
Gift this article